PF-05221304

· Pfizer

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for PF-05221304, covering 2018-05-24 to 2020-09-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease. [Phase 2]

See pricing